iTeos Therapeutics, Inc. Common Stock
ITOS
ITOS: ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
moreShow ITOS Financials
Recent trades of ITOS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ITOS's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers May. 04, 2021
-
Patent Title: Treatment method utilizing pyrrolidine-2, 5-dione derivatives as ido1 inhibitors Sep. 03, 2019
-
Patent Title: Anti-tigit antibodies Jun. 25, 2019
-
Patent Title: Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors Apr. 24, 2018
-
Patent Title: 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use Sep. 12, 2017
-
Patent Title: Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors Mar. 28, 2017
Federal grants, loans, and purchases
Followers on ITOS's company Twitter account
Number of mentions of ITOS in WallStreetBets Daily Discussion
Recent insights relating to ITOS
Recent picks made for ITOS stock on CNBC
ETFs with the largest estimated holdings in ITOS
Flights by private jets registered to ITOS